ANTX insider buying and SEC filings, explained
AN2 Therapeutics, Inc. · CIK 1880438
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$12K
Insiders who bought
1
Sold (not marked 10b5-1)
$81K
Planned sales (10b5-1)
$317K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 9, 2026 | Planned (10b5-1) | Robin Shane Readnour (Director) sold 1,108 shares indirectly at about $6.02 ($7K), marked as a 10b5-1 plan trade. Indirect holdings down <1% to 624,765 shares. | SEC filing Filed Sep 11, 2026 |
| Sep 3–8, 2026 | Planned (10b5-1) | Robin Shane Readnour (Director) sold 16,119 shares indirectly between Sep 3 and Sep 8 at about $6.04 ($97K), marked as a 10b5-1 plan trade. Indirect holdings down 3% to 625,350 shares. | SEC filing Filed Sep 8, 2026 |
| Sep 1, 2026 | Sale | Sarah Joanne Williams (Principal Accounting Officer) sold 272 shares at $5.53 ($2K). Holdings down <1% to 66,311 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 4, 2026 |
| Sep 1, 2026 | Purchase (code P) | Margaret M FitzPatrick (Director) bought 2,098 shares at $5.53 ($12K), reported as a purchase (code P). Holdings up 24% to 10,708 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Robin Shane Readnour (Director) sold 35,402 shares indirectly at about $6.01 ($213K), marked as a 10b5-1 plan trade. Indirect holdings down 5% to 633,867 shares. | SEC filing Filed Aug 19, 2026 |
| Jul 8, 2026 | Sale | Joshua M Eizen (President / COO) sold 5,945 shares at $4.17 ($25K). Holdings down 3% to 206,554 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 10, 2026 |
| May 29, 2026 | Sale | Sarah Joanne Williams (Principal Accounting Officer) sold 265 shares at $4.43 ($1K). Holdings down <1% to 66,583 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 2, 2026 |
| Mar 3, 2026 | Sale | Sarah Joanne Williams (Principal Accounting Officer) sold 327 shares at $1.06 ($347). Holdings down <1% to 66,848 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 5, 2026 |
| Jan 5–6, 2026 | Sale | Lucy Day (CFO) sold 8,807 shares between Jan 5 and Jan 6 at about $1.01 ($9K). Holdings down 10% to 75,363 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Sale | Stephen David Prior (Chief Strategy Officer) sold 6,462 shares between Jan 5 and Jan 6 at about $1.00 ($6K). Holdings down 10% to 59,086 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Sale | Sanjay Chanda (Chief Development Officer) sold 9,251 shares between Jan 5 and Jan 6 at about $1.01 ($9K). Holdings down 11% to 75,823 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Jan 5–6, 2026 | Sale | Joshua M Eizen (President / COO) sold 24,854 shares between Jan 5 and Jan 6 at about $1.00 ($25K). Holdings down 14% to 152,499 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 7, 2026 |
| Nov 4, 2025 | Sale | Joshua M Eizen (President / COO) sold 2,819 shares at $1.14 ($3K). Holdings down 2% to 177,353 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 6, 2025 |
| Nov 4, 2025 | Sale | Stephen David Prior (Chief Strategy Officer) sold 765 shares at $1.14 ($872). Holdings down 1% to 65,548 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 6, 2025 |
39 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ANTX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.